Last reviewed · How we verify
diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy
Approved treatments
- Modeyso · Chimerix
Modeyso works by binding to dopamine receptors in the brain, which helps to slow the growth of cancer cells. - Modeyso · Chimerix
Modeyso works by binding to dopamine receptors in the brain, which helps to slow the growth of cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy patent landscape — cliff calendar, originator estates, attackable patents
- diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy treatment landscape brief
- diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy treatment updates RSS
Frequently asked questions about diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy
What drugs treat diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy?
Tracked treatments include Modeyso.
What is the treatment for diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy?
Standard treatment for diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy includes Modeyso. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy patent cliff · diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy CI report
- Treatment: Modeyso · Chimerix
- Treatment: Modeyso · Chimerix
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing